The international journal of neuropsychopharmacology
-
Int. J. Neuropsychopharmacol. · Jan 2021
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. ⋯ This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133.